Historical Stock Chart
6 Months : From Aug 2019 to Feb 2020
By Colin Kellaher
Amgen Inc. (AMGN) on Monday said it agreed to buy the psoriasis treatment Otezla from Celgene Corp. (CELG) for $13.4 billion in cash in a deal that will pave the way for Bristol-Myers Squibb Co. (BMY) to complete its acquisition of Celgene.
Amgen said the deal is worth about $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits.
Bristol-Myers and Celgene previously agreed to shed Otezla to satisfy regulatory concerns over their union. Bristol-Myers said it expects to complete the acquisition of Celgene by the end of the year.
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires
August 26, 2019 06:59 ET (10:59 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.